|1.||Chiu, Jainn-Shiun: 4 articles (03/2014 - 01/2011)|
|2.||Chen, Yi-Chun: 4 articles (03/2014 - 01/2011)|
|3.||Tseng, Chih-En: 3 articles (03/2014 - 01/2011)|
|4.||Wang, Yuh-Feng: 3 articles (01/2013 - 03/2009)|
|5.||Su, Yu-Chieh: 2 articles (02/2012 - 01/2011)|
|6.||Vantyghem, Marie-Christine: 1 article (11/2015)|
|7.||Bienvenu, Marie: 1 article (11/2015)|
|8.||Legmann, Paul: 1 article (11/2015)|
|9.||Hiéronimus, Sylvie: 1 article (11/2015)|
|10.||Bertagna, Xavier: 1 article (11/2015)|
12/01/1986 - "Comparison of the diagnostic accuracies of these localization studies with the ultimate diagnoses in this group of virilized women showed that: endocrinologic suppression/stimulation studies are of limited value in tumor localization and helpful only in patients with steroidogenic enzyme deficiencies; both selective catheterization and CT scanning may provide spurious localization data; and NP-59 scintigraphy, by depicting both the anatomic localization and functional androgen hypersecretion, may provide the most significant localization data in the evaluation of patients with virilizing syndromes."
08/01/2007 - "An adosterol scintigram showed slight accumulation at the region of adrenal tumor. "
04/01/2006 - "Visualization of an adrenal tumor on NP-59 scintiscan is an unusual finding, which cannot exclude the possibility of malignancy."
04/01/1998 - "Accumulation of NP59 in metastatic adrenal tumors, although a very rare finding, suggests a pitfall in the differential diagnosis of adrenal cortical tumors."
05/01/1996 - "The functional status of this tumor and lack of function of the previously injured right adrenal gland were demonstrated by NP-59 scintigraphy. "
02/01/2002 - "NP-59 is an uncommonly used nuclear medicine technique which is very specific for adenoma when correlated with pathology on other imaging studies. "
12/01/2001 - "Diagnosis of adenoma was based on size and morphovolumetric aspect of the lesion at computed tomography (CT), scintigraphic pattern using NP59 as a tracer, and it was histologically confirmed in 7 patients. "
01/01/1997 - "In the setting of normal adrenal hormonal secretion, the preferential accumulation of 131I-6beta-iodomethyl-norcholesterol (NP59) by adrenocortical tissues allows the distinction of adenomas from other space-occupying or destructive lesions, with diagnostic images being obtained in 100% of lesions > 2 cm. Although some lesions </= 2 cm have yielded nondiagnostic images, the frequency of this phenomenon and thus the utility of NP59 scintigraphy for the evaluation of small adrenal lesions has remained incompletely characterized. "
08/01/1995 - "In the presence of normal biochemistry, a concordant NP-59 imaging pattern is diagnostic of a nonhypersecretory benign adrenal adenoma and requires no immediate therapeutic intervention. "
08/01/1995 - "In this setting, we believe that the functional and anatomical information provided by NP-59 and [75Se]selenomethylnorcholesterol scintigraphy allows one to noninvasively, accurately, and less expensively (Table 9) categorize adrenal masses as benign nonhypersecretory adenomas (the vast majority) vs. a possibly malignant lesion (the minority). "
|3.||Hypertension (High Blood Pressure)
09/01/1983 - "NP-59 adrenal uptake values were 0.20 +/- 0.02%/dose (range, 0.03-0.72), 0.28 +/- 0.04% (range, 0.10-0.65), and 0.14 +/- 0.02%/dose (range, 0.08-0.30) in AA, BAH, and essential hypertension, respectively. "
06/01/2006 - "However, the present study suggests that laparoscopic surgery should be considered even in patients with tumors less than 5 cm in diameter, if both hypertension and accumulation in tumors on NP-59 scintigraphy are present."
09/01/1993 - "In instances when the origin of endocrine hypertension is not forthcoming from CT or MR imaging or when the anatomic and biochemical findings are in conflict, NP-59 or MIBG can almost always provide the answer."
06/01/2006 - "Importantly, all patients who improved hypertension after adrenalectomy displayed strong accumulation in adrenal tumors with visualization of the contralateral gland on NP-59 scintigraphy. "
01/01/2013 - "Among 11 PA patients, eight (73%) had stage 1 hypertension, three (27%) stage 2 hypertension, four (36%) normal plasma aldosterone concentration, nine (82%) nonsuppressed plasma renin activity (PRA), six (55%) normal aldosterone-renin-ratio (ARR), eight (73%) serum potassium ≧3 mEq/L, seven (64%) subclinical presentation, seven (64%) negative confirmatory testing, and four (36%) inconclusive results on CT scan and seven (64%) on planar NP-59 scan. "
|4.||Hyperaldosteronism (Conn Syndrome)
03/01/2014 - "Use of NP-59 SPECT/CT imaging in atypical primary aldosteronism."
01/01/2013 - "We retrospectively analyzed all primary aldosteronism (PA) patients undergoing NP-59 SPECT/CT imaging with regard to their clinicolaboratory and imaging features, investigation, and outcomes. "
01/01/2013 - "NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging features."
02/01/2012 - "Left adrenal aldosteronism was diagnosed by NP-59 SPECT/CT. "
01/01/2011 - "Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism."
11/01/2015 - "Hormonal, Radiological, NP-59 Scintigraphy, and Pathological Correlations in Patients With Cushing's Syndrome Due to Primary Pigmented Nodular Adrenocortical Disease (PPNAD)."
09/01/1990 - "Unusual cause for recurrent Cushing syndrome and its diagnosis by computed tomography and NP-59 radiocholesterol scanning."
05/01/1988 - "Serial NP-59 adrenal images can anticipate the recurrence of Cushing's syndrome after adrenolytic therapy, thereby permitting early retreatment."
04/01/1989 - "In Cushing's syndrome (CS) not only does the pattern of NP-59 uptake depict the adrenal dysfunction and its pathophysiologic basis, but the level of NP-59 accumulation reflects the degree of adrenocortical hyperfunction. "
01/01/1984 - "NP-59 is most commonly used in the diagnosis and management of Cushing syndrome; the second most common use is in the diagnosis of primary aldosteronism. "
|10.||Adrenocorticotropic Hormone (ACTH)